{60 -(p-benzyloxyphenyl)-p-cresol

ABSTRACT

Sulfuric acid esters of bis-(4-hydroxyphenyl)-methane and their pharmaceutically acceptable salts, e.g., sodium bis-(4hydroxyphenyl)-methane sulfuric acid diester, are useful in the treatment of lipidemia.

United States Patent [1 1 Buzzolini et al.

l a-( P- BENZYLOXYPHENYL)-P-CRESOL [75] Inventors: Mario Gustav Buzzolini,

Morristown; Robert Everett Manning, Mountain Lakes, both of N.

211 Appl. No; 442,919

[44] Published under the Trial Voluntary Protest Program on January 28, I975 as document no. B 442,919.

Related US. Application Data [62] Division of Ser. No. 258,787, June I, 1972.

[52] US. Cl 260/613 R; 260/457; 424/303 Dec. 9, 1975 [51} Int. Cl. C07C 43/20 [58] Field of Search 260/613 R [56] References Cited OTHER PUBLICATIONS Bataafsche Pet, M., Derwent Belgian Patents Reports, Vol. 66A, July 15, 1960, C17.

Primary ExaminerBemard Helfin Attorney, Agent, or Firm-Gerald D. Sharkin; Robert S. Honor; Thomas O. McGovern ABSTRACT Sulfuric acid esters of bis-(4-hydroxyphenyl)-methane and their pharmaceutically acceptable salts, e,g., sodium bis-(4-hydroxyphenyU-methane sulfuric acid diester, are useful in the treatment of lipidemia.

1 Claim, N0 Drawings a-(P-BENZYLOXYPHENYL)-P-CRESOL for optimum results. Sulfate ion formed during the This is a division of application Ser. No. 253,787, reaction may be removed by standard techniques, e.g., filed June l, 1972. treatment with barium hydroxide. The product (la) is This invention relates to derivatives of bis-(4-hydrox- 5 recovered by conventional techniques, e.g., evaporayphenyl)-methane. In particular it relates to sulfuric {ion and recrystallization.

acid mono and diesters of bis-(4-hydroxyphenyl)me- The compounds of formula (I) in which R, is hydrothane, methods for preparing the esters, and their use gen may be prepared in accordance with the following in pharmaceutical compositions. reaction scheme:

GM O

Co I The compounds of this invention may be represented The compounds of formula (lb) may be prepared by by the following formula: hydrogenating the compound of formula or a soluble salt thereof in the presence of a hydrogenation catalyst in an inert solvent. The preferred salt forms are c o H (I) the alkali metal salts, preferably sodium. The hydroge- 3. 2 Os 3 nation catalyst is preferably a platinum or palladium catalyst especially 10% platinum or palladium on carbon. The inert solvents preferred are water; esters such as ethyl acetate; the lower alcohols, especially methanol, ethanol, or isopropyl alcohol; and ethers, such as 1 hydrogen, benzyl a and dioxane and tetrahydrofuran or mixtures thereof. The pharmacologically acceptable salts ther temperature of the reaction and the pressure of the Th pref rred mpo n i h sodium saltof hydrogen are not critical in the hydrogenation. The

hydroxyphenyl)-methane sulfuric acid diester. process can be carried out at a temperature of about 0 The compounds of formula (I) in which R is benzyl to C., preferably 20 to 30C., especially between or SO H may be prepared in accordance with the fol- 20 and 25C. The hydrogenation is carried out preferlowing reaction scheme: ably at pressure which vary from about 14 psi (about 1 n 0 @cn G on 130 0:! Base (II) (III) n u ca 0603];

where 50 atmosphere) to about 50 psi. Compound (lb) is recov- X is halo having an atomic weight of about 35 to 80, ered by conventional techniques, e.g., by evaporation R, is hydrogen or benzyl and and recrystallization. R" is benzyl or SO H The compounds of formula (I) form pharmacologiprovided that when R, is benzyl, R", is also benzyl. cally acceptable salts with such cations as sodium, po-

The compounds of formula (la) are prepared by tassium, calcium, magnesium and the like and such treating a compound of formula (II) with a halosulfonie salts are included within the scope of the present invenacid of formula (III) in the presence of a base at a tion. The salts are prepared by conventional techniques temperature of from about 50 to about 30C, The e.g., by dissolving the ester in a suitable solvent, e.g., base used in the reaction can be an inorganic base such Water lower fllkaflol Such as methanol. ethanol and a di h d id or di bi b t or f 50 the like or in a mixture of water and lower alkanol and bl a tertiary amine h as idi i h l i treating the ester with an oxide or hydroxide of the diethylaniline and the like. Although a solvent i not desired cation. Conversely the salts are converted back necessary, it is preferred that the reaction be run in to the esters by with an acid Sulfuric excess amine or in an inert solvent such as hydrocaracid hydrochloric acid and the like in a Similar bons, mg" hexane. benzene, toluene and the like. vent. The compounds of formula (I) and their salts also methylformamide' dimethylacetamide and especially form hydrates, which are included within the scope of carbon disulfide. The preferred temperature range is the Present invention l0C to +10C. The time of the reaction is not criti- The compounds offormula (n) m whlch benzyl cal, but is normally run for about 30 minutes to 2 hours novel and may be prepared by the followlng tron scheme:

3 H @08 OH CH (In) (W) Alkali metal catalyst 11b) where X is as defined above.

The compounds of formula (llb) can be prepared by treating a compound of formula (Ila) with a compound of formula (IV) in the presence of an alkali metal such as sodium, potassium, and the like; alkali metal hydrides, such as sodium hydride, potassium hydride and the like; or an alkali metal salt such as potassium carbonate, preferably sodium or sodium hydride. Although a solvent is not required, it is preferred that the reaction be run in an inert solvent, e.g. dimethylformamide, dimethylacetamide, ethers such as tetrahydrofuran and the like, or acetone when the alkali metal catalyst is potassium carbonate. The temperature is not critical, but is preferred that the reaction be run at between about 50 to about 150C, especially at the reflux temperature of the system. The time of the reaction also is not critical, but for optimum results the reaction should be run for at least 30 minutes. Because the above reaction also yields the dibenzyl ether, the monobenzyl ether (ll) must be separated from it. This can be done by standard techniques, for example, crystallization and column chromatography.

The compounds of formula (Ila), (III) and (IV) are known and may be prepared by techniques which are disclosed in the literature.

The compounds of the formula (I) are useful because they possess pharmacological activity in animals. In particular, the compounds of formula (I) are useful as hypolipidemic agents as indicated by the fall in cholesterol and triglyceride levels in male albino Wistar rats weighing 110-130 g initially. The rats are maintained on drug-free laboratory chow diet for seven days and then divided into groups of 8 to 10 animals. Each group, with the exception of the control, is then given orally 30 milligrams per kilogram of body weight per diem of the compound for six days. At the end of this period, the animals are anesthetized with sodium hexobarbital and bled from the carotid arteries. Serum or plasma samples are collected and 1.0 ml of the serum is added to 9.0 ml redistilled isopropanol. Two autoanalyzer cupsful of a mixture of zeolite-copper hydroxide and Lloydds reagent (Kessler, G., and Lederer, H., I965, Technicon Symposium, Mediad Inc., New York, NY. 345-347) are added, and the mixture is shaken for 1 hour. Cholesterol and triglyceride levels are determined simultaneously on the same sample by Technicon N 24A (cholesterol) and N78 (triglyceride) o o o 5 and the like or parenterally as injectable solutions,

methodology. The mean total serum cholesterol levels suspensions, dispersions, emulsions, and the like. These pharmaceutical preparations may contain up to about of the active ingredient in combination with the carrier or adjuvant.

The lipidemia effective dosage of active ingredient employed for the treatment of lipidemia may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds (I) are administered at a daily dosage of from about 2 milligrams to about 500 milligrams per kilogram of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals, the total daily dosage is from about ISO to about 2000 milligrams. Dosage forms suitable for internal use comprise from about 37.5 to about I000 milligrams of the active compounds in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.

The preferred pharmaceutical compositions from the standpoint of preparation and ease of administration are solid compositions, particularly hard-filled capsules and tablets containing from about 200 to 500 milligrams of the active ingredient.

A representative formulation suitable for oral administration is a capsule prepared by standard encapsulating techniques which contains the following and may be administered 2 to 4 times a day in the treatment of lipidemia:

A solution of 37.5 g. of diethylaniline in 30 ml of carbon disulfide is stirred mechanically and cooled to l0C. To the solution, 12.5 g of chlorosulfonic acid is added dropwise while the temperature is maintained below lOC. Ten grams of bis(4-hydroxyphenyl)methane in 35 ml of carbon disulfide is then added. The mixture is stirred for an hour at room temperature and then poured with stirring into a solution of 8.25 g. of sodium hydroxide and 3.75 g. of hydrated barium hydroxide in 300 ml of water. After extraction with ben zene the aqueous phase is evaporated yielding the product, sodium bis-(4-hydroxyphenyl)methane sulfuric acid diester which is recrystallized from ethanol/water. The sodium bis-(4-hydroxyphenyl)methane sulfuric acid diester of this example is an effective hypolipidemic agent when orally administered to an animal suffering from lipidemia at a dosage of 200 milligrams twice a day.

EXAMPLE 2 Sodium-a-(p-benzyloxyphenyl)-p-cresol sulfate Step A: a-(p-benzyloxyphenyl)-p-cresol To a stirred suspension of 3.36 g of sodium hydride (in mineral oil) in 50 ml of dimethylformamide is added dropwise at room temperature a solution of g bis-(p-hydroxyphenyU-methane in 50 ml dimethylformamide. The resulting solution is stirred at room temperature for l hour. Ten grams of benzyl chloride is added dropwise and the stirring is continued at room temperature overnight. After evaporation of the solvent under reduced pressure, the residue is treated with 100 ml of water and extracted twice with diethyl ether. The combined ether extracts are combined, dried over anhydrous magnesium sulfate, evaporated to dryness, and the resulting oil dissolved in hot ethanol. Bis-p- (benzyloxy)phenyl-methane crystallizes upon cooling and is collected by filtration. The mother liquors are evaporated to dryness and the crystalline mono-addition product is obtained by chromatography on silica gel with chloroform. After separation, the mono-benzyl ether is recrystallized from isopropyl ether, m.p. 9596C.

Step B: Sodium-a-(p-benzyloxyphenyl)-p-cresol sulfate A solution of 21.0 g. of diethylaniline in 7 ml. of carbon disulfide is stirred mechnically and cooled to l0C. To the solution 8.2 g. of chlorosulfonic acid is added dropwise, while the temperature is maintained below 10C. Twenty g of a-(p-benzyloxyphenyl)-pcrcsol in 7 ml carbon disulfide is then added, and the mixture stirred for an hour. The disulfide is removed by distillation under reduced pressure, and the residue is added to a solution of sodium hydroxide (I I2 g) and hydrated barium hydroxide (3.0 g) in 300 ml water with vigorous shaking. The white precipitate which forms is collected by filtration and the product, sodium -a-(p-benzyloxyphenyl)-p-cresol sulfate is recrystallized twice from ethanol.

EXAMPLE 3 Sodium bis-(4-hydroxyphenyl)methane monosulfate ester.

A solution of 9.0 g of the sodium salt of a-(p-benzyloxyphenyl)-p-cresol sulfate in 450 ml methanol and 50 ml ethyl acetate is hydrogenated over 1 g of 10%- palladium on charcoal at atmospheric pressure. The catalyst is then separated by filtration through celite and the solvent evaporated. The white product obtained, sodium bis-(4-hydroxyphenyl)methane monosulfate ester, is recrystallized from isopropanol.

What is claimed is:

l. The phenolic compound which is a-(p-benzyloxy phenyl)-p-cresol. 

1. THE PHENOLIC COMPOUND WHICH IS A(P-BENZYLOXYPHENYL)P-CRESOL. 